🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data | Nature Medicine nature.com/articles/s4159…

#GU35 44% of #kidneycancer pts spend HOURS thinking about cancer. In last 90 days, 36% have gone to ER. >1/3 of patients say that cancer always/often impacts their ability to eat, sleep and engage with family and friends. Surviving is not the same as living. #diseaseburdenzero

Burden of mRCC – Insights from KCCure survey 🛑 36% visited the ER, 23% hospitalized, 44% spend hours daily thinking about cancer 💊 1 in 3 worried about taking too many meds 🧬 More research needed to improve care & QoL! KCCure Dena Battle ASCO Yüksel Ürün #GU25

I really enjoyed this talk by Tian Zhang, MD, MHS #GU25 ASCO. RCC is not Jupiter; it is so heterogenous. We try to refine prognostic criteria all the time and hopefully with molecular features or immune status or KIM1 we will succeed. OncoAlert Toni Choueiri, MD IMDC #sciencewins

RCC is not Jupiter-it’s complex and evolving! 🔥Brilliant discussion at #GU25 ASCO by Tian Zhang, MD, MHS, emphasizing on understanding disease heterogeneity & novel targets to transform treatment strategies. #kidneycancer OncoAlert

Clear cell RCC is heterogeneous. UTSW Simmons Cancer Center’s Tian Zhang, MD, MHS presents the new frontier and dares us to imagine patients unique disease treated uniquely. #GU25 #kidneycancer #diseaseburdenzero

Can’t emphasize enough how this work has transformed my perspective when I see pts in clinic. I definitely am in the group that under appreciated the frequency of this issue. Thx for helping me better understand the patient perspective.

👀 Eye-opening data from Dena Battle & KCCure at #GU25: 🔹 44% of #KidneyCancer patients spend hours thinking about cancer 🧠 🔹 36% visited the ER in the last 90 days 🚑 🔹 >1/3 say cancer always/often impacts eating, sleeping & social life 💔 Surviving is not the same as

Tian Zhang, MD, MHS Simpa Salami Turajlic Lab @ The Crick 💡Adj therapy in #RCC Outstanding presentation of Laurence Albiges about: Adjuvant for who? How to discuss risk of relapse and risks associated with treatment Identify the gaps & next steps in adjuvant setting Oncologists’ Consensus & Patient perspective

70% of health-related internet searches are zero-click - which means pts are relying on snippets and AI overviews for information. When you see something like this that is outdated, misleading, or both - click on the feedback button. It's a small way you can help improve

During her husband's five-year fight with kidney cancer, Dena Battle faced constant uncertainty. The lack of accurate diagnostic tools made treatment decisions challenging, often providing conflicting results and leaving them in doubt. Today, she is a dedicated patient

Glad to have this trial speed thru activation UTSW Simmons Cancer Center ! Enrollment is ongoing!

🎉CONGRATULATIONS to Michael Staehler, recipient of the KCA's 2025 John Fitzpatrick Award recognizing excellence in urology care! The award will be presented at #IKCSEU25, don't miss his lecture! kidneycancer.swoogo.com/IKCSEU25

I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. go.osu.edu/C4w3

It’s my first #AUAAnnualMeeting - can you believe it?! Thanks KCCure for the invite! #AUA2025 #kidneycancer #patientadvocate

I have been fielding a lot of calls from my #medonc colleagues around availability of #microbiome modulating studies for #kidneycancer at City of Hope (in particular, #CBM588). The following are the two studies we have enrolling currently (limited slots remaining): 1.

His final presentation looking at barriers to genetic counseling in RCC. Congrats Paz lotan on an outstanding job at #AUA2025. UW Urologic Oncology UW Urology E Jason Abel Steve Nakada

Join Dr. Sumanta Kumar Pal (Sumanta K. Pal, MD, FASCO) & colleagues on Saturday, May 31, at 6:30 PM CDT/7:30 PM EDT during #ASCO25 for a #RenalCellCarcinoma #MedEd event. Produced with @KCCure. bit.ly/4mdScJu #KidneyCancer #Oncology

📣 Live at #ASCO25: Learn from real-world #RCC cases with Sumanta K. Pal, MD, FASCO, Dr. McDermott & Tian Zhang, MD, MHS  ✅ IO-based regimens  ✅ Sequencing therapies  ✅ Shared decision-making  🗓️ May 31 | 7:00 PM CDT  🔗 bit.ly/RCC-T

🎉 Just 2️⃣ days away! Join PeerView for 15+ expert-led #CME symposia May 30–31 at #ASCO25! 🍽️ Dinner included 🎓 Free CME 🚌 McCormick shuttles to: Gate 31 – Hyatt Gate 26 – Hilton Gate 21 – Sheraton 🔗 bit.ly/Onc25T ❌ No ASCO reg needed for PeerView events only